Polianta Ltd’s Alexion Pharmaceuticals ALXN Stock Holding History

Polianta Ltd’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-9,300	Closed	-$910K	–	104
2019 Q3	$910K	Buy	+9,300	New	+$1.05M	0.58%	61

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Polianta Ltd's ALXN Position: Q4 2019 in Review

Polianta Ltd sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 9,300 shares — an estimated $910K sold.

Polianta Ltd first reported a position in ALXN in Q3 2019 and held it in 1 quarter. The position peaked at $910K in Q3 2019. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

Polianta Ltd reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Polianta Ltd sold 9,300 Alexion Pharmaceuticals shares in Q4 2019, an estimated $910K.
Polianta Ltd first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Polianta Ltd's Alexion Pharmaceuticals position peaked at $910K in Q3 2019.
667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Polianta Ltd's 13F filing for Q4 2019, filed 13 Jan 2020.